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Abstract. Unlike silica nanoparticles, the potential of silica mesoparticles (SMPs) (i.e. particles 
of submicron size) for biological applications in particular the in vitro (let alone in vivo) cellular 
delivery of biological cargo has so far not been sufficiently studied. Here we examine the 
potential of luminescent (namely, octahedral molybdenum cluster doped) SMPs synthesised by a 
simple one-pot reaction for the labelling of cells and for protein transduction into larynx 
carcinoma (Hep-2) cells using GFP as a model protein. Our data demonstrates that the SMPs 
internalise into the cells within half an hour. This results in cells that detectably luminesce via 
conventional methods. In addition, the particles are non-toxic both in darkness and upon photo-
irradiation. The SMPs were modified to allow their functionalisation by a protein, which then 
delivered the protein (GFP) efficiently into the cells. Thus, the luminescent SMPs offer a cheap 
and trackable alternative to existing materials for cellular internalisation of proteins, such as the 
HIV TAT protein and commercial protein delivery agents (e.g. Pierce™). 
Introduction 
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Silica nanoparticles (SNPs) and mesoporous silica nanoparticles (MSNPs) have been actively 
studied for a wide range of biomedical applications,1, 2 due to their high inertness, 
biocompatibility and large specific surface area.1, 3 These nanoparticles were successfully used 
for the cellular delivery of nucleic acids,3 proteins,4 drugs against various types of diseases5 and 
imaging agents,6 etc. However, there is general concern about the acute and/or chronic toxicities, 
as well as the environmental impact caused by nanoparticles.7, 8 Indeed, despite great effort in 
recent decades of the development of biomedical applications of nanoparticles, only a few 
therapeutic nano-formulations have been approved by the US Food and Drug Administration 
(FDA).9 Therefore, there is a justified rationale for the study and development of biomedical 
delivery platforms based on larger particles.10-13 This general interest resulted in mesoporous 
silica microparticles (MSMPs), which also recently became a subject of intensive studies in the 
context of biomedical applications.14-19 Surprisingly, conventional silica mesoparticles (SMPs) 
were studied in this context to a far lesser extent with only a handful of reports for amorphous 
silica mesoparticles.10-13, 20, 21 These reports nevertheless suggested that SMPs may not only 
internalise in mammalian cells, but that they may also be less cytotoxic than corresponding 
nanoparticles.10-13, 20 In contrast, polymer particles of sub-micron sizes, which are both 
biodegradable and non-biodegradable, are well established in the cellular delivery of biological 
active cargos.22-31 Interestingly, it was noticed that both SMPs and polymer particles with the 
sizes of 500+ nm tend not to localise in lysosomes, which are the organelles responsible for 
digestion and removal of wastes.20, 32 Such behaviour of these mesoparticles makes them 
particularly interesting for their application as cellular delivery vehicles, since the biological 
cargo delivered by the particles is less likely to breakdown within the cells before the cargo 
serves its purpose. 
In order to easily observe the cellular internalisation of particles by conventional methods (e.g. 
by confocal microscopy), they are typically surface-modified by fluorescent dyes via a chemical 
process that usually includes at least two studies: 1) surface functionalisation and 2) attachment 
of a luminescent tag. If the particles are also required to deliver a biologically active cargo, 
further stages of material modification are required, such as the loading or the attachment of the 
biological cargo via covalent bonding.  
During our recent studies  to develop luminescent materials that lack the drawbacks of 
commodity organic dyes such as poor photostability and self-quenching, we have identified the 
highly photoluminescent material, (Bu4N)2[Mo6I8(NO3)] (Fig. S1), as a particularly handy 
precursor for a range of luminescent materials.33-37 Specifically, we showed that red emitting 
mono-disperse SNPs and SMPs that have sizes of 50 nm and 500 nm, respectively, can be easily 
prepared via slightly modified Stöber process in a one-step reaction.35 In this process tetraethyl 
orthosilicate (TEOS) is hydrolysed by ammonia in the presence of the cluster. Using this 
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process, cluster cores {Mo6I8}4+ that luminesce have been incorporated into silica matrices. The 
molybdenum cluster doped SNPs were shown to be internalised into the larynx carcinoma (Hep-
2) cells. The molybdenum cluster were also shown to have low cytotoxicity in darkness, yet have 
significant photo-induced cytotoxicity upon UV/blue light irradiation.34 
Since the potentials of SMPs in biomedical applications are generally not studied in detail (if 
studied at all), we evaluate here the toxicity of SMPs in the dark and their photo-induced 
toxicity, the cellular internalisation kinetics and the capability of the above red emitting SMPs to 
act as cellular delivery vehicles using, for the sake of comparison, the same culture line, i.e. Hep-
2. Importantly, we demonstrate that molybdenum cluster doped SMPs can be successfully 
applied to protein transductions (i.e. internalisation of proteins into cells, from the external 
environment), where Green Fluorescent Protein (GFP) was used as a model protein. 
Experimental Section 
Materials 
All reagents and solvents were purchased from Alfa Aeser, Sigma Aldrich or Fluka and were 
used as received without further purification. (Bu4N)2[{Mo6I8}(NO3)6] was prepared according 
to the described procedures.33 The human larynx carcinoma cell line (Hep-2) was purchased 
from the State Research Center of Virology and Biotechnology VECTOR (Russia) and cultured 
in Eagle’s Minimum Essential Medium (EMEM, pH = 7.4) supplemented with a 10% fetal 
bovine serum under a humidified atmosphere (5% CO2 and 95% air) at 37°C. 
Synthesis of {Mo6I8}0.01@SiO2 mesoparticles 
Mesoparticles {Mo6I8}0.01@SiO2 with average particle sizes of 500 nm were synthesised 
according to the previously reported  method.35 In general, 6 mL of an acetone solution 
containing the cluster complex (Bu4N)2[{Mo6I8}(NO3)6] (1.35 mg) was placed in a 10 mL vial. 
TEOS (0.5 mL), H2O (0.75 mL) and 25% aqueous ammonia solution (0.5 mL) were added to the 
vial, while stirring vigorously. The vial was capped and stirred for 12 h at room temperature. The 
yellow solution obtained was centrifuged at 7000 rpm for 10 min, washed by several 
sonication/centrifugation cycles (five times with acetone and five times with water) and finally 
dried at 60 °C in air. Neat SMPs were obtained following a similar procedure but without the 
cluster. The mean particle size was assessed by TEM (Libra 120, Zeiss) and they were similar to 
values that were reported earlier,35 i.e. ∼500 nm. 
Surface functionalisation of {Mo6I8}0.01@SiO2 by glycidyl-groups (glycidyl-
{Mo6I8}0.01@SiO2) 
50 mg of powdered {Mo6I8}0.01@SiO2 was dispersed in 2.5 mL of hexane by sonication for 30 
min. 0.0075 mL of Et3N and 0.05 mL of (3-glycidyloxypropyl)trimethoxysilane were then added 
to the dispersion and the resultant mixture was heated at 55 °C for 3.5 h under gentle stirring. 
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The product of the reaction, i.e. functionalised SMPs were then separated by centrifugation at 
7000 rpm for 10 min and washed five times with hexane and one time with acetone by 
sonication/centrifugation cycles and finally dried at ambient conditions. 
Conjugation of glycidyl-{Mo6I8}0.01@SiO2 with Green Fluorescent Protein 
({Mo6I8}0.01@SiO2-GFP) 
10 mg of glycidyl-{Mo6I8}0.01@SiO2 was washed twice with 5 mL of buffer solution (0.1 M 
NaCl) and resuspended in 1 mL of the coupling buffer (Na2CO3 and NaHCO3 in the 
concentrations 5.8 mg·mL−1 and 3.8 mg·mL−1, respectively, giving a final pH = 10). 30 μL of 
GFP (10 mg·mL−1) mixed with 1 mL of the coupling buffer was added to the dispersion of SMPs 
and gently stirred for 24 h. Thereafter, the resultant dispersion was washed with 5 mL of buffer 
solution, resuspended in 2 mL of the quenching solution (glycine : Triton X-100 : d/d water = 50 
mg : 0.014 mL : 20 mL) and mixed gently for 30 min. Finally, the conjugate was washed again 
with 5 mL of the buffer solution and resuspended in 1 mL of storage buffer (Triton X-100 : 
Phosphate buffered saline (PBS) = 0.023 mL : 50 mL having final pH = 7.4). The final 
concentration of the conjugate was 10 mg·mL−1. The experiment was repeated for non-
functionalised {Mo6I8}0.01@SiO2 to demonstrate the importance of the glycidyl functionalisation 
for binding of GFP. 
MTT-assay 
The effect of neat SiO2, {Mo6I8}0.01@SiO2 and {Mo6I8}0.01@SiO2-GFP on the cells metabolic 
activity was determined using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT) colourimetric assay. The Hep-2 cells were seeded into 96-well plates at 7×103 cells/well 
in a medium containing SMPs with concentrations from 1.5 to 1500 μg·mL–1 and then incubated 
for 24 h under 5% CO2 atmosphere. 10 μL of the MTT solution (5 mg·mL–1) was added to each 
well, and the plates were incubated for a further 4 h. The formazan produced was then dissolved 
in DMSO (100 μL). The optical density of the solutions was measured with a plate reader 
Multiskan FC (Thermo scientific, USA) at a wavelength of 570 nm. The experiment was 
repeated on three separate days. 
Cellular internalisation assay 
Hep-2 cells were seeded on a 96-well µ-plate (Ibidi GmbH, Germany) at a density of 7×103 
cells/well and incubated overnight at 37 °C under 5% CO2 atmosphere. The medium was then 
replaced with a fresh medium containing 0.1 mg·mL–1 of {Mo6I8}0.01@SiO2 or 0.02 mg·mL–1 of 
{Mo6I8}0.01@SiO2-GFP or 20 µg·mL–1 GFP and incubated for 18 h. The cells incubated in the 
absence of the studied agents were used as a control. Finally, the cells were washed twice with 
PBS, fixed in 4% paraformaldehyde, and visualised using an IN Cell Analyzer (GE Healthcare, 
USA). The nuclei of cells were stained with Hoechst 33342 (Thermo Fisher scientific), the 
cytoskeletons were visualised with Alexa Fluor™ 532 Phalloidin (Sigma Aldrich). A 375 nm 
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excitation source was used with a 700 nm emission filter for visualizing {Mo6I8}0.01@SiO2 
particles, 375/488 for Hoechst, 531/554 for Phalloidin and 488/530 for {Mo6I8}0.01@SiO2-GFP 
and GFP. 
Cellular uptake kinetics 
Hep-2 cells were seeded in 6-well plates at a density of 3×105 cells per well. They were 
incubated for 24 h to reach a confluency greater than 50%. {Mo6I8}0.01@SiO2, 
{Mo6I8}0.01@SiO2-GFP and GFP were diluted in EMEM medium to a final concentration of 0.1 
mg·mL–1 for {Mo6I8}0.01@SiO2 and 0.02 mg·mL–1 for {Mo6I8}0.01@SiO2-GFP or 20 µg·mL–1 for 
GFP. The cells were then cultivated with substances in the culture medium for 0; 0.25; 0.5; 2; 4; 
8 and 16 hours at 37 °C under a 5% CO2 atmosphere. After treatment, the cells were rinsed three 
times with ice cold phosphate buffered saline (PBS) to remove any unbound materials. The cells 
were then trypsinizated and resuspended in fresh PBS with 10% fetal bovine serum. The cell 
suspensions were analysed using CytoFlexS (Beckman Coulter, USA). A 375 nm excitation 
source was used with a 695±40 nm emission filter for {Mo6I8}0.01@SiO2 and 488 nm excitation 
source was used with a 530±30 nm emission filter for {Mo6I8}0.01@SiO2-GFP and GFP. Gating 
was utilised via a negative sample and the data were expressed as percentage of the fluorescent 
positive cells.  The mean fluorescence was obtained from a population of 10 000 cells for each of 
the assays. 
Photoinduced cytotoxicity study 
The Hep-2 cells were seeded in 96-well plates at a density of 7×103 cells/well and cultured for 24 
h. The medium was then replaced with a fresh medium containing {Mo6I8}0.01@SiO2 in 
concentration of 0.15−0.0046 μg·mL–1 and incubated for 24 h and the cells were then illuminated 
with 500 W halogen lamp (λ ≥ 400 nm) for 30 min to apply a total light dose of 20 J·cm–2. The 
cells cultured in the SMP free medium were used as a control. Cell viability was assayed 24 
hours after irradiation using MTT-assay. 10 μL of the MTT solution (5 mg·mL–1) was added to 
each well, and the plates were then incubated for 4 h. The resultant formazan was then dissolved 
in DMSO (100 μL). The optical density was measured with a plate reader Multiskan FC (Thermo 
scientific, USA) at a wavelength of 620 nm. The experiment was repeated on three separate 
days. 
TEM imaging 
The Hep-2 cells were first cultivated as described in the cellular internalisation assay. Thereafter, 
the cells were collected with 0.5% trypsin-EDTA and washed with a 0.1M phosphate buffer 
three times. The pre-fixation of the cells was performed in glutaraldehyde for 2 hours. The cells 
were then fixated in 1% osmium tetraoxide and gradually dehydrated in ethanol. Finally, the 
cells were gradually infiltrated with Epon. Specimens were cut over a glass knife using an 
ultramicrotome Leica EM UC7 to get 70 nm thin sections on copper grids with 200 mesh. The 
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grids were stained with uranyl acetate and lead citrate. TEM images were taken using LEO 910 
transmission electron microscope (ZEISS). 
Statistical analysis 
The Mann-Whitney U test was used to perform the statistical analysis of the unpaired data. P 
values of less than 0.01 were considered significant. The data is presented as mean values ± 
SEM (standard error of the mean). 
Results and Discussion 
Materials Synthesis and Characterization 
Red emitting mesoparticles {Mo6I8}0.01@SiO2, i.e. silica doped by {Mo6I8}4+ were obtained and 
characterised by methods reported elsewhere.35 To summarise the earlier results, it was found 
that luminescent cluster units {Mo6I8}4+ in the particles bond to silica matrices via Mo-O-Si 
covalent bonds and hydrogen bonds (e.g. Mo-OH2···O(H)-Si), which prohibit any cluster 
leaching. All SMPs are spherical with an approximate size of 500 nm (Fig. S2). The particles 
absorb UV and visible wavelengths up to 550 nm and emit in the region 600-830 nm with the 
maximum of emission at ∼700 nm. The photoluminescence quantum yield was 0.08.35 The 
particles are also capable of the generation of some singlet oxygen, but at least 4 times less 
efficiently in comparison to the corresponding SNPs of 50 nm, due to the smaller specific 
surface area of the larger particles. These properties (emission in the red region combines with 
relatively poor ability to generate singlet oxygen) make these SMPs attractive for biolabeling and 
bioimaging applications as well as a traceable cellular delivery vehicle for a biological cargo. 
Protein transduction is an emerging technology that can be used to study the functions of 
proteins and enzymes as well as to deliver therapeutic proteins.29, 38, 39 It can be performed either 
when a protein is chemically bonded to the delivery vehicle or when it is not bonded (i.e loaded) 
onto or within the vehicle. Both modes of use have their own advantages and disadvantages 
depending on their application.40 Specifically, in the context of in vivo applications, rigid linkage 
between the carrier and the protein can be extremely important to avoid cargo leakage. 
Therefore, to evaluate the potential of the luminescent SMPs in this application we have 
functionalised the surface of the particles {Mo6I8}0.01@SiO2 with epoxy groups using (3-
glycidyloxypropyl)trimethoxysilane, which allows consequent conjugation of silica with 
proteins.41, 42 Glycidyl-functionalised {Mo6I8}0.01@SiO2 SMPs were then conjugated with Green 
Fluorescent Protein (GFP) to produce stable suspensions of {Mo6I8}0.01@SiO2-GFP particles in 
an aqueous medium (Scheme 1). GFP is indeed a convenient model protein for this study, firstly, 
because its’ emission does not interfere with that emanating from the clusters and secondly in its’ 
free form, GFP does not effectively internalise into cells.43-45 
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Scheme 1. The synthetic procedure of {Mo6I8}0.01@SiO2-GFP. 
It is well-known that proteins are capable of adherence or adsorption onto the surface of silica 
due to non-covalent interactions.46, 47 Therefore, it is crucial to demonstrate that the glycidyl 
modification of silica is important for protein labelling. {Mo6I8}0.01@SiO2, non-functionalised 
{Mo6I8}0.01@SiO2 treated by GFP and the conjugated material {Mo6I8}0.01@SiO2-GFP were 
analysed by flow cytometry (FACS). According to our data, all of the particles had the same 
intensity of red emission, i.e. no damage to the molybdenum cluster had occurred during 
subsequent reactions (Fig. 1A). Moreover, {Mo6I8}0.01@SiO2-GFP particles are at least 4.5 times 
more emissive in the green wavelength region than the non-functionalised {Mo6I8}0.01@SiO2 
particles treated by GFP (Fig. 1B, Fig. S3). Thus, the glycidyl surface modification of 
{Mo6I8}0.01@SiO2 does indeed significantly increase the ability of the particles to bind to 
proteins. 
 
Fig. 1. FACS data for {Mo6I8}0.01@SiO2 (red), non-functionalised {Mo6I8}0.01@SiO2 treated by GFP 
(blue) and the conjugated material {Mo6I8}0.01@SiO2-GFP (magenta). A) Red and green emission 
intensity of the particles. B) Number of particles vs. the intensity of green emission (530±30 nm). 
Cellular uptake and localisation of {Mo6I8}0.01@SiO2 mesoparticles 
The cellular uptake of SNPs is thoroughly documented in the literature, while studies on the 
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cellular internalisation and localisation of silica particles of above 200 nm are quite rare,20, 48-50 
despite the fact that SMPs were generally shown to be less cytotoxic in comparison with 
nanoparticles.10-13, 20 Here, the uptake of GFP, {Mo6I8}0.01@SiO2 and {Mo6I8}0.01@SiO2-GFP by 
Hep-2 cells was analysed using fluorescent microscopy, flow cytometry (FACS) and 
Transmission Electron Microscopy (TEM). 
Characteristic fluorescent microscope images of Hep-2 cells taken after cultivation with GFP and 
the SMPs are presented in Figure 2. These images allow us to draw several important 
conclusions. Firstly, both {Mo6I8}0.01@SiO2 and {Mo6I8}0.01@SiO2-GFP internalise into Hep-2 
cells, as can be observed in the red emissions, which are localised throughout the whole 
cytoplasm volume of the cells. Secondly, GFP itself does not penetrate into the cells in 
accordance with other studies.43-45 Finally, green emissions are observed that coincide with the 
location of the red emissions of the SMPs. The green emissions are associated with GFP within 
the cells treated by {Mo6I8}0.01@SiO2-GFP, which signifies that GFP does penetrate as a part of 
the conjugate with the SMPs. 
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Fig. 2. Cellular uptake of {Mo6I8}0.01@SiO2, {Mo6I8}0.01@SiO2-GFP and GFP by fluorescent microscopy. 
The cell nuclei were labelled with Hoechst 33342 (blue), the cytoskeleton with Phalloidin (orange), GFP 
– green fluorescence protein (green) and theluminescent particles (red). The control images are for cells 
incubated in the absence of the analytes. 
FACS studies further support the above conclusions of the successful internalisation of both 
{Mo6I8}0.01@SiO2 and {Mo6I8}0.01@SiO2-GFP. Indeed, the cells incubated with both types of 
SMPs showed significant increase of luminescence in comparison with the negative control 
(untreated cells), while the cell incubated with native GFP did not show any noticeable increase 
in luminescence (Fig. 3A). 
The kinetics of internalisation – indicated by the percentage of luminescent Hep-2 cells vs. time 
(Fig. 3B) shows that the internalisation of the particles {Mo6I8}0.01@SiO2-GFP is the most 
intensive within the first hour and plateaus after 4 hours, while it is noticeably slower for 
{Mo6I8}0.01@SiO2 even though the cells were incubated at a higher concentration of particles. 
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Some discrepancy of the uptake kinetics between {Mo6I8}0.01@SiO2-GFP and {Mo6I8}0.01@SiO2 
are likely due to both the difference in the surface coating of the particles and the agglomeration 
of the particles that is less significant in the case of {Mo6I8}0.01@SiO2-GFP (Fig. S3, S4). 
 
Fig. 3. FACS assay results. A) Hep-2 Cells sorting depending on the time of incubation with 0.1 mg mL-1 
of {Mo6I8}0.01@SiO2 (λex = 488 nm, λem = 695±40 nm), 0.02 mg mL-1 of {Mo6I8}0.01@SiO2-GFP or 20 
µg·mL–1 GFP (λex = 488 nm, λem = 530±30 nm); B) Percentage of luminescent Hep-2 cells vs. incubation 
times. 
Unlike nanoparticles, both pinocytosis and phagocytosis are the most expected mechanisms of 
internalisation for mesoparticles.51, 52 TEM images (Fig. 4 and S5) of the cells after 
internalisation with {Mo6I8}0.01@SiO2 and {Mo6I8}0.01@SiO2-GFP demonstrated that regardless 
of whether they had a cargo or not, the particles were localised inside of the single-layer vesicles 
located in the cellular cytoplasm. Moreover, no extracellular fluid was observed in the vesicles 
surrounding the particles, i.e. the vesicles engulfed the particles very closely (Fig. 4B and 4D). 
This observation indicates that the most likely mechanism of cellular internalisation for the 
SMPs is phagocytosis.53, 54 We have also observed the particles within early endosomes (Fig. 
4C), while particles in lysosomes (or, indeed, fusion of phagosomes with lysosomes) were not 
observed. This observation is in the agreement with the earlier work on size-dependent silica 
particles internalisation in cervical cancer cells (HeLa), where no SMPs were found within the 
lysosomes.20 The high inertness of the SMPs (see below) is the most likely reason why the 
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particle containing phagosomes fail to fuse with lysosomes. Such a fate of the particles within 
the cells suggests that they can be present in the cellular cytoplasm for long time without any 
active excretion and any significant damage to the cargo they bear. 
 
Fig. 4. Reprisentative TEM images of Hep-2 cells: A) Control cells. B-D) The cells after 12 hours of 
incubation with SMPs. The red arrow shows SMPs engulfed in a single-layer vesicle. The yellow arrow 
shows SMPs in an early endosome. 
Cytotoxicity of {Mo6I8}0.01@SiO2 and {Mo6I8}0.01@SiO2-GFP 
The standard MTT-assay technique was used to evaluate the cytotoxicity of the SMPs samples 
on the Hep-2 cells. The assay was undertaken in the presence of serum for the sake of 
comparison with the related earlier study on SNPs.34 Note that several studies indicate that neat 
silica particles were found to be more toxic in the absence of serum.20, 55-57 The results of MTT 
assay are presented in Figure 5. For comparison, the MTT assay was also undertaken for neat 
SMPs and particles with varied loading of the cluster (Fig. S6). The half-maximal inhibitory 
concentrations (IC50) values for the SMPs are summarised in Table 1. The rate of the 
metabolically active cells was determined against the negative control. According to data 
obtained, SiO2 and cluster-doped particles have similar values of cellular toxicity. Namely, in the 
concentration range from 0.01 to 0.18 mg·mL–1, the SMPs did not affect viability of the cells, 
while at higher concentrations, these particles lead to reduced cellular viability and proliferation. 
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This toxicity pattern is very similar to those found for related cluster-doped SNPs, which have a 
particle size of 50 nm.34 The usable concentrations for practical biomedical applications for 
either type of the materials are thus recommended to not exceed 0.18 mg·mL–1. 
 
Fig. 5. Cytotoxicity of {Mo6I8}0.01@SiO2 SMPs for Hep-2 cells (up) and {Mo6I8}0.01@SiO2-GFP 
conjugate (bottom). 
{Mo6I8}0.01@SiO2-GFP demonstrated significantly higher cellular toxicity: the determined IC50 
value was approximately 50 times lower than that for non-conjugated material. This result is in 
the agreement with other studies, for example review 58 summarises various mechanisms of GFP 
cytotoxicity. The noticeable increased dark toxicity of GFP conjugated material observation is 
not only the additional evidence of successful internalisation of GFP but also demonstrates that 
GFP remains active within the cells 
Table 1. IC50 values for the SMPs. 
 SiO2 
{Mo6I8}n@SiO2 {Mo6I8}0.01@SiO2-
GFP n = 0.0005 n = 0.001 n = 0.005 n = 0.01 
IC50, 
(mg·mL–1) 1.27 ± 0.03 0.86 ± 0.01 0.92 ± 0.01 1.06 ± 0.02 0.94 ± 0.01 0.022 ± 0.002 
Evaluation of the photo-induced cytotoxic effect on Hep-2 cells 
We have earlier demonstrated that both molybdenum cluster doped SNPs and SMPs are capable 
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of singlet oxygen generation.34, 35 Moreover we have shown that this ability of the SNPs causes 
significant photo-induced cytotoxicity. Since the above results confirm that molybdenum cluster-
doped SMPs, despite having larger sizes, successfully penetrate into the Hep-2 cells and tend to 
localise within the whole volume of cytoplasm, it is vital to evaluate the photo-induced cellular 
toxicity of the material associated with the presence of the cluster. 
The MTT assay technique was then used to determine the viability of Hep-2 cells cultivated with 
{Mo6I8}0.01@SiO2 in the non-toxic range 0.0046 – 0.15 mg mL-1 for 24 h and irradiated for 30 
min with λ > 400 nm. Our data show that {Mo6I8}0.01@SiO2 demonstrate slightly increased 
photoinduced cytotoxicity in comparison with neat SMPs, which were non-toxic under radiation 
within the whole range of the studies concentrations (Fig. 6). However, even at the highest 
studied concentration of {Mo6I8}0.01@SiO2, 0.15 mg·mL–1, the percentage of the living cells 
after photoirradiation for 30 min was more than 80%. For comparison, the percentage of the 
living Hep-2 cells incubated with {Mo6I8}0.01@SiO2 nanoparticles at the same concentration 
after the same time of irradiation was found to be 20%.34 
 
Fig. 6. Photoinduced cytotoxicity of {Mo6I8}0.01@SiO2 on Hep-2 cells. 
Overall the photo-induced cytotoxicity of SMPs is only slightly higher than that found for other 
sub-micron size materials doped by {Mo6I8}4+. For example the survival rate of Hep-2 cells 
treated by {Mo6I8}@MIL-101 was ~93%,59 while no photo-induced cytotoxic effect was found 
for polystyrene-based materials {Mo6I8}@PSS.60 
Conclusions. 
In conclusion, this work demonstrates that SMPs doped by luminescent molybdenum cluster is a 
highly attractive material for biomedical application, in particular for the bioimaging and 
biolabeling of cells, as well as for the cellular delivery of biological molecules, such as proteins. 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Firstly, this luminescent material is obtained in a one-stage process using inexpensive precursors 
and no organic surfactants. It does not contain “fragile” organic parts that could be damaged in 
the consequent reactions of functionalisation or loading with a biological cargo and photo-
irradiation. Secondly, the material is compatible with well-established methods to functionalise 
silica. To demonstrate this, we have functionalised the particles with glycidyl groups and 
subsequently conjugated the particles with GFP protein. Thirdly, the particles themselves have 
very low levels of both dark and photo-induced cytotoxicity and they can be used in the 
concentrations up to 0.18 mg·mL−1. Fourthly, the particles were shown to efficiently internalise 
into Hep-2 cells following phagocytosis and localise within the whole volume of cytoplasm. 
Notably, the particle loaded phagocytes tend to fuse with early endosomes rather than the 
lysosomes. The emission from the particles within the cells was intensive enough to be detected 
by conventional methods, not only by very sensitive FACS method, but also by confocal 
microscopy. Finally, using GFP we have demonstrated that molybdenum cluster doped SMPs 
can efficiently deliver a biological cargo into a cell, where the efficiency of the delivery of the 
cargo can be easily monitored by the emission from the SMPs. Overall, this study demonstrates 
that sub-micron SMPs produced by conventional surfactant-free Stöber process have a high 
potential for biomedical applications, in particular in the context of protein delivery. This study 
should be further supported with further detailed in vitro and in vivo studies to allow this 
exceptionally cheap material to fully exploit its potential. 
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